-

ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024

VICTORIA, British Columbia--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024.

AI Driven Drug Discovery Summit
Date: Thursday, November 14
Time: 11:30 pm EST
Format: Fireside Chat

To register for the event, please click Here

Meet with us

For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA, at Quantum Media: jen@quantum-corp.com, +1.917.214.3514.

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

Contacts

Investor Relations Contact
Kirsten Beduya
Quantum Media Group, LLC
kirsten@quantum-corp.com

Industry:

ImmunoPrecise Antibodies Ltd.

NASDAQ:IPA
Release Versions
EnglishFrench
$Cashtags
$IPA
$nvda
$xbi
Hashtags
#AI
#DrugDiscovery
#TechBio
#antibodies
#foundationai
#generativeai
#llm

Contacts

Investor Relations Contact
Kirsten Beduya
Quantum Media Group, LLC
kirsten@quantum-corp.com

Social Media Profiles
Linkedin
IPA on X
More News From ImmunoPrecise Antibodies Ltd.

MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today reported financial results for its fiscal 2027 first quarter ended July 31, 2026. The quarter marked the commercial launch of ReefIQ™, MindWalk's data platform, and the start of its shift toward recurring, platform-based revenue. Revenue increased 21.3% year over year to $3.8 million. Gross profit increased 47.1% to $2.2 million; gross margin expanded to 58.6% from 48.3%. Net cash...

MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it has entered into a binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to US$30 million. The facility is intended to support MindWalk’s biologics programs, commercial expansion, working capital, and general corporate purposes. The facility carries a fixed annual interest rate of 7.00%, accruing only on amounts drawn, an...

MindWalk to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today announced that it is participating in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14 - 16, 2026 at the Lotte New York Palace Hotel in New York, where a pre-recorded fireside chat with Chief Executive Officer Dr. Jennifer Bath is available to registered attendees on demand. “The question institutional investors are working through is where durable v...
Back to Newsroom